https://en.wowtale.net/2025/06/04/231246/

This interview with AbFinder Therapeutics from WOWTALE highlights the company's innovative PepFc technology, designed to overcome significant challenges in antibody-drug conjugate (ADC) development. The article explains how AbFinder aims to improve cancer treatments by addressing issues like antibody miniaturization for better tumor penetration, half-life extension to ensure drug longevity, and toxicity reduction by eliminating harmful interactions. It details AbFinder's B2B business model, offering PepFc licensing, antibody discovery services, and proprietary pipeline development, positioning the company as a key player in the evolving biopharma market. The text emphasizes the team's expertise and the market potential for their solutions in both cancer and other therapeutic areas.